Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441955 | 0.84 | CYP1A2 (0.45) | CYP1A2TDP1POLBEPHX2 | |
| SCHEMBL4550241 | 0.84 | POLB (0.50) | CYP1A2TDP1POLBHSD17B10HRH3 | |
| SCHEMBL24192451 | 0.81 | USP2 (0.50) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL13088446 | 0.80 | POLB (0.55) | CYP1A2TDP1POLBHSD17B10HRH3 | |
| SCHEMBL31397626 | 0.79 | CYP1A2 (0.43) | CYP1A2TDP1POLBHSD17B10HRH3 | |
| SCHEMBL13627077 | 0.79 | HRH3 (0.48) | CYP1A2TDP1POLBHSD17B10HRH3 | |
| SCHEMBL10075487 | 0.78 | POLB (0.58) | POLBHSD17B10HRH3MEN1KMT2A | |
| SCHEMBL13088457 | 0.78 | POLB (0.58) | POLBHSD17B10HRH3MEN1KMT2A | |
| SCHEMBL13453747 | 0.78 | POLB (0.58) | POLBHSD17B10HRH3MEN1KMT2A | |
| SCHEMBL18479438 | 0.78 | PHGDH (0.42) | POLBHSD17B10HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | Epizyme, Inc. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| EP-4351552-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794543-A | Combination therapy with SETD2 inhibitors | EPIZYME股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. | 2023-03-09 | — | — | US | disclosed |
| EP-4107157-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-115380033-A | SETD2 inhibitors and related methods and uses, including combination therapies | EPIZYME股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | CCNE1, CCNE2, FOXM1 | SETD2 947/4885NSD2 641/4885CYP2C8 163/4885 |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | FOXM1, CCNE2, CCNE1 | SETD2 1006/4885NSD2 644/4885CYP2C8 163/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SETD2 1/4885NSD2 35/4885CYP2C8 3214/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SETD2 3/4885NSD2 14/4885CYP2C8 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.